Bifalgorithm post · Colorectal Cancer: Full Treatment Guideline · A Result You Can Hold In Your Hands

Published Results

Published Results (Colorectal Cancer: Full Treatment Guideline · A Result You Can Hold In Your Hands) — "These are not experimental long shots; they are establ…

Ideas in this flowchart

  • Established cancer therapies show meaningful outcomes, but individual expectations vary.
  • These are established therapies with published results, not experimental long shots.
  • In the pivotal VISION trial, Lutetium-177 radioligand therapy added to standard care extended median overall survival in advanced prostate cancer from 11.3 to 15.3 months.
  • In metastatic melanoma, modern immunotherapy increased five-year survival from under 10% to roughly 34–52%.
  • In one landmark melanoma trial, about half of the patients who responded were still alive ten years later.
  • Dendritic-cell vaccination was linked to median survival of 19–23 months in advanced prostate cancer, compared with nomogram predictions of 11–13 months.
  • For unresectable liver cancer, TACE regularly achieves median survival of 15–24 months.
  • What any one person can expect depends on individual clinical factors.
  • Diagnosis affects the expected outcome.
  • Disease stage affects the expected outcome.
  • General condition affects the expected outcome.
  • Each case is assessed honestly before anything is recommended.
Bifalgorithm
Sign up
Feed/

Published Results

No cover

Channel

Colorectal Cancer: Full Treatment Guideline

1 page

U
USR292600b83e2a
Ebook2w

"These are not experimental long shots; they are established therapies with published results. In the pivotal VISION trial, adding Lutetium-177 radioligand therapy to standard care extended median overall survival in advanced prostate cancer (15.3 vs 11.3 months). In metastatic melanoma, modern immunotherapy has lifted five-year survival from under 10% in the chemotherapy era to roughly 34–52%, and in one landmark trial about half of the patients who responded were still alive ten years later. Dendritic-cell vaccination has been linked to median survival of 19–23 months in advanced prostate cancer, where standard nomograms predicted 11–13. In unresectable liver cancer, TACE regularly achieves median survival in the 15–24 month range. What any one person can expect depends entirely on their diagnosis, stage, and general condition — which is exactly why each case is assessed honestly before anything is recommended."

Flowchart preview
👍
0
0 comments0 shares

Sign in to view and post comments.